Pages that link to "Q36693320"
Jump to navigation
Jump to search
The following pages link to Clinical genetics for the pulmonologist: introduction (Q36693320):
Displaying 29 items.
- Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy (Q27316983) (← links)
- Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen (Q28833852) (← links)
- Engineering of stable bispecific antibodies targeting IL-17A and IL-23. (Q33519833) (← links)
- Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent (Q33523566) (← links)
- Stability engineering of scFvs for the development of bispecific and multivalent antibodies (Q33574335) (← links)
- A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo (Q33688219) (← links)
- Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin (Q33985577) (← links)
- Genetic predisposition to respiratory diseases: infiltrative lung diseases (Q34010166) (← links)
- Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity (Q34575855) (← links)
- Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. (Q35119802) (← links)
- A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells (Q36216038) (← links)
- Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease). (Q36886900) (← links)
- Engineered proteins pull double duty (Q37725479) (← links)
- Emerging antibody combinations in oncology (Q37893414) (← links)
- Smarter drugs: a focus on pan-specific monoclonal antibodies (Q37952285) (← links)
- Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. (Q38038410) (← links)
- Bispecific antibodies for viral immunotherapy (Q38992408) (← links)
- LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies (Q39250618) (← links)
- Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis (Q39302290) (← links)
- Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies (Q39557682) (← links)
- Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy (Q39679526) (← links)
- Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. (Q39753915) (← links)
- Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry (Q40353620) (← links)
- A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells (Q40612349) (← links)
- Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies (Q41838529) (← links)
- Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation. (Q46783569) (← links)
- New magic bullets can hit more than one target (Q47424609) (← links)
- Interferon dimers: IFN-PEG-IFN. (Q47939716) (← links)
- Wikidata:Database reports/Constraint violations/P698 (← links | edit)